Cointime

InventisBio

company

About

InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.

  • 1 - 10

Highlights

Total Funding Amount
$247M
Funding Rounds
4
Investors
2

Details

Last Funding Type
Series D
Last Funding Money Raised
$147M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$247M
InventisBio has raised a total of $247M in funding over 2 rounds. Their latest funding was raised on Sep 27, 2020 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 27, 2020 Series D $147M 2 — — Detail
Mar 12, 2019 Series C $70M 1 — — Detail
May 30, 2017 Series B $19M 1 — — Detail
Jan 1, 2016 Series A $11M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
InventisBio is funded by 2 investors. Pudong Innotek and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Pudong Innotek — Series D
Lilly Asia Ventures — Series D
Cointime
เนื้อหา
บริษัท